CDK2 and neoplasm: While co-targeting cdk2 and cdk4/6 with endocrine therapy is promising in the pre-clinical setting, most of these approaches are associated with continued tumor proliferation and tumor relapse, and in most cases, failure to respond to treatment can be fatal.